Friday 6 November 2026 Export BSX’s income statement to Excel — free account

Boston Scientific Corporation

Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024.

Revenue: +1.44%
EPS: −21.6%
Free cash flow: −25.3%
Total debt: +3.04%

Quarter to September 2026, against a year earlier

42.73 1.91 −4.28%

Follow BSX

Alert me

Market cap: $64.7B
P/E: 18.7×
Fwd P/E: 17.0×
Dividend yield: —
F-score: 7/9
Altman Z: 5.41
Beneish M: −2.49
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Boston Scientific Corporation (BSX) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Boston Scientific Corporation (BSX) trades at a price to free cash flow of 19.3×. Over the past ten years it has ranged from 17.3× (July 2026) to 7,034× (March 2019); the current reading is higher than 3% of that period. That is below the Medical Devices industry median of 28.8× and below the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/BSX/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Boston Scientific Corporation price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/BSX/metrics/price-to-free-cash-flow">Boston Scientific Corporation (BSX) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	38.6×	(22.34%)
FY2024	49.7×	5.96%
FY2023	46.9×	(32.31%)
FY2022	69.3×	52.51%
FY2021	45.4×	2.04%
FY2020	44.5×	(2.22%)
FY2019	45.5×	(99.25%)
FY2018	6,101×	19,397.92%
FY2017	31.3×	(12.05%)
FY2016	35.6×	(36.14%)

Period	Price to free cash flow	Change
Sep 2026	19.0×	9.67%
Jun 2026	17.3×	(35.44%)
Mar 2026	26.8×	(30.51%)
Dec 2025	38.6×	2.01%
43 more quarters	Free account

Against its own ten years

Low 17.3× High 7,034×

Ten-year median 49.7×

Current reading's percentile 3

Company	Price to free cash flow
PHG Koninklijke Philips N.V. compare	14.1×
BSX Boston Scientific Corporation	19.3×
GEHC GE HealthCare Technologies Inc. compare	19.9×
MDT Medtronic PLC compare	21.8×
ABT Abbott Laboratories compare	25.2×
STE STERIS plc compare	26.4×
DXCM DexCom, Inc. compare	28.8×
SYK Stryker Corporation compare	28.9×
EW Edwards Lifesciences Corporation compare	41.5×
Medical Devices industry median	28.8×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Boston Scientific Corporation (BSX) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on BSX

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on BSX

Stockrow Weekly